Biogen said fourth-quarter total revenue was $2,455 million, up 3% year-over-year, and full-year total revenue was $9,676 million, down 2% year-over-year. Full-year GAAP diluted EPS was $11.18 and Non-GAAP diluted EPS was $16.47.

1. 01

   Biogen said fourth-quarter total revenue was $2,455 million, up 3% year-over-year, and full-year total revenue was $9,676 million, down 2% year-over-year. Full-year GAAP diluted EPS was $11.18 and Non-GAAP diluted EPS was $16.47.

2. 02

   The company disclosed that fourth-quarter Multiple Sclerosis product revenue was $1,070 million, down 8%, and Rare disease revenue in the same quarter was $535 million, up 13%. Fourth-quarter global SKYCLARYS revenue was approximately $102 million.

3. 03

   Biogen said full-year 2024 net cash flow from operations was approximately $2.9 billion and free cash flow was approximately $2.7 billion. As of December 31, 2024, cash and cash equivalents were approximately $2.4 billion, total debt was approximately $6.3 billion, and net debt was approximately $3.9 billion.

4. 04

   The company said full-year 2025 Non-GAAP diluted EPS is expected to be in the range of $15.25 to $16.25. It also expects full-year 2025 total revenue to decline by a mid-single digit percentage at constant currency compared to 2024.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.